Our pipeline

MG 7331

At Mereo, we unlock the potential of rare disease therapies that were not being progressed in pharmaceutical or biotechnology companies – creating new possibilities for all our stakeholders, from our investors to the patients that need us most.

We have already delivered five successful Phase 2 studies and a Phase 1b/2 ongoing. Our pipeline currently consists of six clinical-stage product candidates. Click below to see the relevant scientific publications for our products. 

Core programs

Product

Setrusumab (BPS804)

For the potential treatment of Osteogenesis Imperfecta (“OI”), a rare genetic bone condition affecting children and adults.

Product

Alvelestat (MPH966)

For the potential treatment of severe Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD) and Bronchiolitis Obliterans Syndrome (BOS).

Product

Etigilimab (MPH313)

For the potential treatment of patients with advanced or metastatic
solid tumors.

Core programs

Partnered and Partnering Opportunities on Non-Core Programs

We have one additional program with current partnering opportunities. Navicixizumab has been licensed out to OncXerna and leflutrozole has been licensed to ReproNovo.

Product

Navicixizumab (OMP305B83)

For the potential treatment of platinum-resistant ovarian cancer, partnered with OncXerna Therapeutics Inc. for further development.

Product

Acumapimod (BCT197)

For the potential treatment of acute exacerbations of chronic obstructive pulmonary disease (“AECOPD”).

Product

Leflutrozole (BGS649)

A novel once weekly oral aromatase inhibitor. Partnered with ReproNovo for further development.

Pipeline News

Image
Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
08 January 2024

LONDON, January 08, 2024 – Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an update on its pipeline programs as well as an update on recent corporate developments. 

Image
Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)
14 October 2023

NOVATO, Calif., VANCOUVER, British Columbia and LONDON, UK — Oct. 14, 2023 — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Mereo BioPharma Group plc (NASDAQ: MREO) today announced interim data from the Phase 2 portion of the Phase 2/3 Orbit study demonstrating that treatment with setrusumab (UX143) significantly reduced incidence of fractures in patients with OI with at least 6 months of follow-up and continues to demonstrate ongoing and meaningful improvements in lumbar spine bone mineral density (BMD). The data were presented in a late-breaker presentation at the American Society for Bone and Mineral Research 2023 Annual Meeting (ASBMR). 

Image
Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference
21 September 2023

London, September 21, 2023 - Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the 2023 Cantor Global Healthcare Conference on Wednesday, September 27, 2023 at 10:55am ET /03:55pm BST.

Image
Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
06 July 2023

NOVATO, Calif. — July 06, 2023 — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the first patients have been dosed in both of its late-stage clinical trials evaluating setrusumab in pediatric and young adult patients with OI sub-types I, III and IV. The Phase 3 portion of the pivotal Phase 2/3 Orbit study is evaluating the effect of setrusumab compared to placebo on annualized clinical fracture rate in patients aged 5 to <26 years. The newly initiated Phase 3 Cosmic study is an active-controlled study evaluating setrusumab compared to intravenous bisphosphonate (IV-BP) therapy on annualized total fracture rate in patients aged 2 to <5 years.